Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast

Rowland Noakes
Queensland Institute of Dermatology, Greenslopes Private Hospital Campus, Greenslopes, QLD, Australia

Background: Scleroderma is traditionally managed with immunomodulatory agents such as methotrexate, mycophenolate mofetil and corticosteroids. There are anecdotal reports for, and theoretical reasons why, the anti-fibrotic agent tranilast may provide an additional treatment modality.

Objective: The objective of the current study was to demonstrate if the addition of topical tranilast to an established regime resulted in an improvement in the Localized Scleroderma Assessment Tool (LoSCAT) and modified Rodnan score.

Patients and methods: A small double-blinded randomized prospective study of 11 pairs of treatment sites in four patients; three with morphea and one with limited scleroderma was performed. All patients continued with their prescribed treatment and applied 0.1% betamethasone valerate in PCCA PraçaSil™ (B) to the control site with 0.1% betamethasone valerate and 1% tranilast (B/T) to the comparator site over a period of 3 months. Photographs and monthly LoSCAT scores were performed on the morphea patients and a modified Rodnan score on the limited scleroderma patient. Statistical analysis was via sign test.

Results: The mean baseline LoScat score at the B treated sites was 6.6 which improved to 4.3 (p = 0.16). The mean baseline LoScat score at the B/T treated sites was 5.75 which improved to 2.8 following treatment. (p = 0.04)

Limitations: This was a small single center study. The ideal concentration of tranilast is unknown. As all patients continued with standard management the expected response may be less than would have been anticipated in a single agent trial.

Conclusion: The role of tranilast in the management in scleroderma warrants further investigation in larger trials.

Keywords: morphea, limited scleroderma, tranilast, kynurenine

Introduction
Scleroderma is a disorder characterized by cutaneous, and in systemic variants, systemic sclerosis. Systemic variants display respiratory, esophageal and renal involvement or esophageal involvement only. The latter is known as limited scleroderma. Previously the acronym CREST (Calcinosis, Raynaud’s, Esophageal dysmotility, Telangiectasia) was used to describe this syndrome.
The term morphea is used to describe scleroderma where only the skin is involved. Recognized variants include frontoparietal, plaque, linear, generalized, subcutaneous, keloidal and a pan sclerotic variant. Atrophic variants known as Atrophoderma of Pasini and Pierini, Parry–Romberg syndrome, and linear atrophoderma of Moulin are also recognized. Eosinophilic fasciitis is included in the morphea spectrum by many authorities.1

The etiology of this class of disorders is poorly defined but they are classified as autoimmune diseases due to their known association with other autoimmune diseases and the presence of auto-antibodies.3

Endothelial injury is proposed to be the initiating event.4 The initial cellular infiltrate is monocytic,5 a class of leucocytes known to express the kynurenine pathway (KP).6 Subsequently lymphocytes are present in the inflammatory infiltrate, dominated by TH1 and TH17 cells7 which express a profibrotic cytokine profile.8 The cytokine profile later shifts to TH2+ presumably under the influence of the KP.

The KP is the metabolic pathway by which L-tryptophan is converted to nicotinamide. In addition, it serves an important immune regulatory role by controlling the availability of the essential amino acid L-tryptophan within the microenvironment.9 As the least common of the essential amino acids, L-tryptophan availability is a rate limiting factor for cell division and thus T cell proliferation. T lymphocytes monitor L-tryptophan availability via a GCN2 kinase,10 activation of which promotes T cell apoptosis.11 The rate limiting enzyme is indoleamine 2,3 dioxygenase (IDO)12 which is induced by interferon gamma13 thus providing a negative feedback loop on immune stimulation and vascular endothelial growth factor (VEGF)14 which is expressed in response to endothelial injury.15 The relationship to T cell apoptosis is complex however with kynurenine metabolites selectively promoting the apoptosis of TH1 cells16 with preservation of the TH2 cells thus promoting a TH2 skewed cytokine environment. In addition, several KP metabolites are natural ligands of the aryl hydrocarbon receptor17–19 binding to which releases pp60src which plays a role on fibroblast activation.20

Expression of the principal fibroptic cytokine transforming growth factor beta (TGF beta) is altered in scleroderma.21 Pathogenic antibodies generated in the TH2 skewed environment include those directed against fibrillin122,23 which inhibit the sequestration of TGF beta by the extracellular matrix, matrix-metalloproteinase-1 (MMP-1) antibodies which inhibit collagenase activity24 and anti-endothelial antibodies25 which perpetuate endothelial damage. Finally, TGF beta is known to promote IDO expression26 this generating further KP metabolites providing a positive feedback loop.

Tranilast (N-[3,4-dimethoxycinnamoyl]-anthranilic acid) is an agent approved in Japan and South Korea for the management of allergic and fibrotic disorders. It is a derivative of the kynurenine metabolite 3-hydroxyanthranilic acid. Its reported actions include the inhibition of chemical mediator release,27 the inhibition of fibroblast proliferation and collagen production28 and modulation of the KP.29–31

PCCA PracaSil™ (Professional Compounding Chemists of America, Houston, TX, USA) is a compounded anhydrous silicone base containing Pracaxi oil. Pracaxi oil is derived from the seeds of the Pentaclethra macroloba tree. It contains oleic, linoleic, and behenic fatty acids, and oleic acid has been reported to enhance the absorption of topical tranilast in rats.32

Patients and methods
Ethical approval and registration
Ethics approval was obtained from the Greenslopes Private Hospital Ethics Committee (Newdegate Street Greenslopes, QLD, Australia) and the trial was registered with the Australian New Zealand Clinical Trials Registry (ANZCTR) as: Assessing the response of limited scleroderma to manipulation of the KP. A prospective study comparing topical corticosteroids vs topical corticosteroids/tranilast- Universal Trial Number (UTN) U1111-1177-3064.

Written informed consent was obtained from all participants.

Study population
A total of 11 pairs of treatment sites in four patients were identified. Exclusion criteria included pregnancy, age <18 years, documented allergy to ingredients and significant hepatic, renal, or hematological disease.

Ages ranged from 21 to 90 and diagnoses included plaque, linear and generalized morphea, and limited scleroderma.

All patients continued with their routine therapy. This varied form sole therapy in plaque disease and limited scleroderma to methotrexate in generalized morphea and methotrexate and hydroxychloroquine in linear morphea. Patient characteristics and treatments are summarized in Table 1. All systemic agents had been introduced prior to enrollment in the trial and doses remained unchanged during the trial.

Study design
Betamethasone valerate 0.1% in pralisal (B) was used as a control with betamethasone valerate 0.1% and tranilast 1%
Table 1  Patient characteristics

<table>
<thead>
<tr>
<th>Characteristics (sex, age)</th>
<th>Diagnosis</th>
<th>Adjuvant therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female, 21 years</td>
<td>Plaque morphea</td>
<td>Nil</td>
</tr>
<tr>
<td>Male, 90 years</td>
<td>Limited scleroderma</td>
<td>Methotrexate 20 mg weekly, hydroxychloroquine 400 mg daily</td>
</tr>
<tr>
<td>Female, 25 years</td>
<td>Linear morphea</td>
<td>Nil</td>
</tr>
<tr>
<td>Male, 77 years</td>
<td>Generalized morphea</td>
<td>Methotrexate 10 mg weekly</td>
</tr>
</tbody>
</table>

in prasical (B/T) at the contralateral treatment site. Both agents were prepared by a registered compounding pharmacy (Wickham House Compounding Pharmacy, Brisbane, QLD, Australia).

A total of 11 pairs of treatment sites were identified. Randomization was done via the MS Excel random number function. Number one was used to assign B/T application to the proximal/right treatment site with B to the comparator site and number two to assign B application to the proximal/right treatment site with B/T to the comparator site. The list was provided to the study coordinator who liaised with the patients. The investigators were blinded to the randomization protocol. Each treatment site was palm sized. Thirty grams per month was used at each treatment site.

The study population was provided with written instructions including diagrams on where and how to apply the trial agents and reviewed accordingly. All treatment sites were spatially separated by areas of clinically noninvolved skin except for the patient illustrated in Figure 1A where the two plaques were immediately adjacent but considered morphologically sufficiently distinct to assess the responses to treatment.

Assessment was via Localized Scleroderma Assessment Tool (LoScat). Assessments were performed by the same observer and photographs of the involved sites were taken. At the completion of the study LoScat scores and images were collated, and scores confirmed. A representative series of images are shown in Figure 1A–E. The LoScat scores were performed at treatment sites only. This included all the involved areas in all subjects apart from one plaque in the subject with generalized morphea which was not suitable for inclusion.

Safety
No adverse events were reported.

Results
Overall the mean baseline LoScat score at the B treated sites was 6.6 which improved to 4.3 following treatment (p=0.16). The mean baseline LoScat score at the B/T treated sites was 5.75 which improved to 2.8 following treatment (p=0.04). This was derived from the addition of the Localized Scleroderma Activity Skin Index (mLoSSI) and the Localized Scleroderma Skin Damage Index (LoSDI).

Considering each component individually the mean of the mLoSSI at the B treated sites improved from 4.1 to 2.5. The LoSDI at the B treated sites deteriorated marginally from 2.5 to 2.75. At the B/T sites the mean mLoSSI improved from 3.9 to 1.4 and the LoSDI improved from 1.9 to 1.4.

In the limited scleroderma patient, the mean modified Rodnan score improved from a baseline of 2 at both the B and B/T sites to a mean of 1.3 at the B treated sites and 1 at the B/T treated sites.

The Physician Global Assessment of Activity (PGA-A) improved from 52 at baseline to 25 at the B sites (p=0.03) and 51 to 17.5 at the B/T sites (p=0.01)

The Physician Global Assessment of Damage (PGA-D) improved from 32.5 at baseline to 27 at the B sites (p=0.31), and 35 to 21 at the B/T treated sites (p=0.45).

The correlation was stronger between the LoScat and PGA-A scores compared to PGA-D as has been previously reported.33

Interestingly no disease progression was noted at the B/T treatment sites whereas disease progression was noted at two of the B treatment sites. One is shown in Figure 1C and D. The before and after images in Figure 1C reveal progression at the B treatment site over a 3-month period whereas no progression is seen at the adjacent B/T treatment site.

Discussion
These results are consistent with previous case reports which support a role for tranilast in the management of scleroderma, primarily as an adjuvant to established therapies. Interestingly only combined therapy with systemic agents where indicated, and a combination of topical betamethasone and tranilast demonstrated statistically significant improvement at a 3-month interval indicating that variants of this disease with a poorer prognosis, that is variants near joints, frontoparietal variants, and generalized variants require aggressive management early in the course of the disease if complications are to be prevented. The limited improvement in the PGA-D score at all sites is consistent with the observation that once tissue damage is established treatment is unlikely to reverse it in the short term.

The rarity of morphea makes the establishment of evidence-based guidelines difficult. The best evidence exists for methotrexate in combination with systemic steroids and UVA1 therapy.34
There are anecdotal reports of success in treating morphea with tranilast and its known properties indicate it is an agent whose potential needs further exploration. Upregulation of the KP has been demonstrated in morphea and there are sound theoretical reasons, as outlined above, why targeting this pathway may provide a more targeted therapy.

**Limitations**

This study, by necessity, has several limitations. First, the disease incidence is 2.7 per 100,000 which limits to the size of the study population. Second, the fact tranilast was added to established therapies reduced the measured effect. Third, the bioavailability of topical tranilast is not well

---

**Figure 1** (A). Plaque morphea. Pre- (left side) and immediate posttreatment images. Betamethasone treatment site is labeled b and betamethasone/tranilast site is labeled BT. Persisting erythema indicating ongoing disease activity is noted at the b site whereas the disease has resolved with post inflammatory hyperpigmentation at the BT site. (B) Linear morphea. Pre- and immediate posttreatment images at the b treatment site demonstrating disease progression has occurred over 3 months. (C) Linear morphea. Pre- and immediate posttreatment images at the Figure 1B adjacent BT treatment site demonstrating no disease progression. (D) Limited scleroderma. Immediate posttreatment image. There is persisting induration at the b site compared to the BT treatment site. (E) Linear morphea post treatment image. The BT has improved more quickly than the b site at the completion of the 3-month trial.

**Abbreviations:** b, betamethasone; BT, betamethasone/tranilast;
established however studies in rats indicate that topical delivery, especially with agents to enhance absorption, may be a more effective means of delivery than oral administration.32

Interestingly no disease progression was detected at the B/T treated sites whereas it was noted at two B treated sites. One example is shown in Figure 1C and D where progression is noted over a 3-month period at the B treated site (Figure 1C) whereas no progression is noted at the B/T site (Figure 1D).

As tranilast’s major mechanism of action involves the TGFβ pathway36 and the principle pharmacological effects in morphea is anti-fibrotic the LoSCAT scoring system, which includes inflammatory markers may not be the ideal means of assessing the response to tranilast treatment. In this regard changes in the modified Rodnan used in the patient with limited scleroderma may more directly measure the response to tranilast therapy.

The lack of disease progression at treated sites was an interesting finding suggesting the drug may be targeting the disorder more specifically than established therapies. Further evaluation of the role of the KP in cutaneous sclerosing disorders is warranted as targeted therapies against this pathway may offer more specific treatment.

Disclosures

The author has no conflicts of interest in this work.

Reference